CASI completes enrollment in Phase II of ENMD-2076 for TNBC

In April, CASI Pharmaceuticals Inc. (NASDAQ:CASI) completed enrollment of 41 patients in a Phase II trial of ENMD-2076 in previously treated patients with locally advanced or metastatic triple-negative breast cancer (TNBC). The open-label, U.S. trial is evaluating 250 mg oral ENMD-2076 daily in 28-day cycles. The primary endpoint is clinical benefit rate (CBR)...